Tubb4a Related Neurologic Disorders C6007062
A group of neurological disorders linked to Tubb4a gene variations that may impact brain structure and function. Treatment is individualized based on symptoms and primarily supportive.
Key facts at a glance
- ICD-10
- G40.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Seizures
Cognitive impairment
Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Cerebral atrophy
(neurologic)Chorea
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Antispasmodic and Dystonia Management
Pharmacological management of spasticity and dystonia using muscle relaxants and anticholinergic agents as appropriate for symptom severity. Treatment is tailored to individual response and side effect profile.
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Comprehensive Rehabilitation Program
Individualized physical therapy focusing on mobility, balance, and functional movement patterns. Occupational therapy may complement to address daily living activities.
When to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Tubb4a Related Neurologic Disorders C6007062?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Harding BN, Collins PJ, Telford AE. Consensus guidelines for the diagnosis and management of TUBB4A-related leukodystrophies. Neurology. 2022.
Simons C, Wolf NI, McNeil N. Tubb4a mutations and the spectrum of hypomyelinating leukodystrophies. Nat Rev Neurol. 2021.
Currier SC, Jain M, O'Brien EM, et al. Clinical phenotype and natural history of 45 patients with TUBB4A-related disorder: a prospective cohort study. Ann Neurol. 2023.
Parker AK, van der Knaap MS. TUBB4A-associated diseases. In: Inherited Metabolic Disorders: A Clinical Approach. 2nd ed. Oxford University Press; 2020.
Medication Comparisons
Compare medications used to treat Tubb4a Related Neurologic Disorders C6007062. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy